News Formal

Gilead settles patent case around HIV drug Descovy - San Francisco Business Times

  • 📰 SFBusinessTimes
  • ⏱ Reading Time:
  • 29 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 15%
  • Publisher: 68%

日本 ニュース ニュース

日本 最新ニュース,日本 見出し

$GILD sees settlement of patent suit creating a smoother transition to longer-acting HIV prevention drugs PrEP AIDS

HIV drug pioneer Gilead Sciences Inc. made sure its leadership spot is well protected into 2032, settling a case this week with the makers of five potential generic versions of its second-generation HIV prevention drug Descovy.

, which would be groundbreaking because it would be injected just under the skin only twice a year to treat HIV. Gilead also is studying lenacapavir as a possible long-term PrEP medication. The HIV prevention market, which tailed off like other drug markets during the height of Covid-19 pandemic lockdowns, grew in the first couple quarters of this year, O'Day said.

It wasn't clear what else the companies may have received in return for agreeing in U.S. District Court in Delaware to delay commercialization of their lower-cost generics.

このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

 /  🏆 78. in JP
 

コメントありがとうございます。コメントは審査後に公開されます。

日本 最新ニュース, 日本 見出し

Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。

Berkeley pizza joint adds new location in Stonestown Galleria - San Francisco Business TimesThis would make two S.F. mall stops for the longtime pizza fixture on Telegraph Avenue.
ソース: SFBusinessTimes - 🏆 78. / 68 続きを読む »

Vir Biotechnology opens new office in St. Louis - San Francisco Business TimesThe San Francisco-based immunology company that wants to help eradicate infectious disease globally has expanded its footprint in St. Louis, opening a new $41 million office within the Cortex innovation district. It says the new facility will be critical to advancing research to treat several infectious diseases, including Covid-19.
ソース: SFBusinessTimes - 🏆 78. / 68 続きを読む »